loading page

Vaccines against the cold chain
  • +1
  • Aswin Doekhie,
  • Nunuk Nurulita,
  • Didik Setiawan,
  • Asel Sartbaeva
Aswin Doekhie
University of Bath
Author Profile
Nunuk Nurulita
Universitas Muhammadiyah Purwokerto
Author Profile
Didik Setiawan
Universitas Muhammadiyah Purwokerto
Author Profile
Asel Sartbaeva
University of Bath
Author Profile

Abstract

Vaccines require continuous refrigeration to retain their efficacy as most vaccine components are derived from mammalian or microbial origin which are thermally unstable. Continuous refrigeration, known as the vaccine cold chain, comes at a cost that directly correlates to the standard of infrastructure that is available. A break in the cold chain caused by poor infrastructure can result in direct loss of functionality in these lifesaving medicines. Therefore, several approaches have been suggested to mitigate these losses. Not only will these benefit general healthcare via improved shelf-life but also enhanced resistance to thermal fluctuations and, in some cases, improved drug target localisation. In this minireview, we highlight trends in vaccine thermal stabilisation and look to the future for cold chain logistics.

Peer review status:UNDER REVIEW

05 May 2021Submitted to British Journal of Pharmacology
12 May 2021Assigned to Editor
12 May 2021Submission Checks Completed
21 May 2021Reviewer(s) Assigned